

Index

- AAMI. *See* age-associated memory impairment
- ACBS. *See* Anticholinergic Cognitive Burden Scale
- ACSH. *See* ambulatory care-sensitive hospitalization
- activities of daily living (ADLs)
 functional assessment of, 35
 LTC and, 1
- acute psychiatric illness. *See* psychiatric illness
- AD. *See* Alzheimer disease
- addictive disorders, 242–247
- ADEs. *See* adverse drug events
- adjustment disorder, 142–143
 with anxiety, 221
- ADLs. *See* activities of daily living
- advance care planning, 312–313
 loss of DMC and, 313
- advance directives, 284
- adverse drug events (ADEs), 334
 clinical case for, 349
 prevention strategies for, 348–349
- affective psychosis, 175–179
 clinical case for, 177–178
 mania with, 179
 MDD with, 175–177
- age-associated memory impairment (AAMI), 64–65
 brain and memory wellness plans, 65, 66, 379
 cognitive training strategies for, 66
 SCI and, 65
- aggressive behaviors. *See also* violence
 during end-of-life care, 319
 psychosocial factors for, 76
 psychotic disorders and, 165, 198–202
 assessment of, 198
 homicide and, 198
 prevention strategies for, 198–202
 protective factors for, 201
 risk factors for, 199–200
- aging
 anorexia of, 260
 with BPSD, 95
 MDD and, 95
 with MNCDs, 95
 personality disorders and, 235, 236–237
 sleep-wake disorders and, 225
- agitated delirium, 103
- agitation
 during end-of-life care, 319
 as expression of BPSD, 50, 70–71, 76, 83–85, 86, 383
- agnosia, 47–48
- agoraphobia, 214–215
 clinical case of, 214–215
- alcohol abuse
 assessment of, 27
 CSDH and, 62
 MNCDs from, 60
 psychotic disorders and, 197
- alcohol use disorder, 244
- Alzheimer disease (AD), 43–51
 agnosia and, 47–48
 anxiety and, 205–206
 aphasia and, 47–48
 apraxia, 48
 BEHAVE-AD, 36
 biological factors for, 71
 biomarkers for, 49
 clinical presentation of, 47
 delirium and, 115
 diagnosis of
 criteria for, 47
 genetic testing in, 70
 with MRI, 47
 testing as part of, 47
 DLB differentiated from, 52–53
 Down syndrome and, 47
 executive dysfunction and, 48
 FTDs differentiated from, 52–53
 genetic factors for, 43–47
 incidence rates for, 43
 late-onset MDD and, 130
 in LTC populations, 5–6
 MCI and, 65–67
 MDD as distinct from, 68
 mild, 50
 MMSE for, 32–34
 MNCD with psychotic symptoms and, 190
 moderate, 50–51
 BPSD and, 50
 EPS with, 50–51
 MDD and, 50
 nutritional disorders with, 269–270
 probable, 47
 psychotic disorder and, 172
- risk factors for, 43–47
 secondary psychotic disorders and, 190
 severe, 51
 stages of, 48–51
 Grossberg-Desai staging scale, 48–51
 pre-MNCD, 48–50
 terminal, 51
 treatment based on, 80–82
 strength-based stages of, 366
 treatment of
 with ChEIs, 80–82
 with memantine, 80, 82–83
 by stage, 80–82
 variants of, 47
- ambulatory care-sensitive hospitalization (ACSH), 314
- amlodipine, 261
- ANH. *See* artificial nutrition and hydration
- animal-assisted approaches, in wellness care plans, 377
- anorexia, 260–261
 of aging, 260
- anoxic brain injury, 63
- anticholinergic burden, 335–338
- Anticholinergic Cognitive Burden Scale (ACBS), 335–338
- anticholinergic drugs
 reduction strategies for, 334–343
 safer alternatives to, 342–343
- anticipatory prescriptions, 315
- anticonvulsants, 357
- antidepressants
 for bipolar disorder, 154–155
 during end-of-life care, 323
 for malnutrition, 271
 for MDD, 132–136, 137–138, 139, 140, 148
 for MNCD with psychotic symptoms, 191
 SSRIs, 88
 for MDDs, 148
 for SIBs, 93
- antipsychotic medications. *See also* deprescribing of medications; potentially inappropriate prescribing
 as high-risk, 346–347

- for MNCD with psychotic symptoms, 192
 for psychotic disorders, 185–187
 for schizophrenia, 180
- anxiety
 AD and, 205–206
 adjustment disorder with, 221
 defined, 205
 delirium and, 218
 eczema and, 358
 end-of-life care and, 321–324
 fear and, 205
 MDD with, 129, 205–206
 medications linked with, 207
 MNCD and, 205
 PDD and, 205
 prevalence rates for, 205–206
 psoriasis and, 358
- anxiety disorders, 205–213
 agoraphobia, 214–215
 clinical case of, 214–215
 common types of, 205
 complications of, 206
 consequences of, 206
 diagnosis of, 206
 differential, 206
 with GAI, 206
 test workup for, 211
 GAD, 207–213
 clinical case for, 211–213
 in LTC populations, 209–210
 medical conditions as cause of, 217–218
 hypoglycemia, 217
 medication-induced, 217
 MNCDs and, 215–217
 clinical case for, 216–217
 treatment for, 216
 panic disorder, 214–215
 causes of, 214
 clinical case of, 214–215
 treatment of, 214
 premorbid, 216
 social, 215
 specific phobias, 215
 substance-induced, 218
 treatment of, 206–207
 benzodiazepines in, 213, 347
 evidence-based approaches in, 212
- apathy syndrome, 149–151
 clinical case for, 150–151
 common causes of, 149
 symptoms of, 149–150
 treatment approaches to, 150
- aphasia, 47–48
 apraxia, 48
- aripiprazole, 86–87
 for MNCD with psychotic symptoms, 191
 for PDP, 196
 for treatment-resistant MDD, 139
- armodafinil, 230
- artificial nutrition and hydration (ANH), 289
- asenapine, 196
- assessment processes, psychiatric
 for alcohol abuse, 27
 of allergies, 27
 of biological needs, 21–22
 for BNPS, 19–20, 26–27
 etiology of, 20
 excess disability, 20
 medical history and, 27–29
 protections from, 22
 for BPSD, 85–86
 caregiver environments and, 21–22
 by caregivers, 30
 for cognitive disorder, 123–125, 173–174
 dehydration, 261
 for delirium, 104–111, 112
 for family caregivers during, 114
 standardized tools for, 106–107
 work-up in, 105–111
 developmental history as factor in, 29
 documentation of, 39–40
 elements of, 19
 of environmental needs, 21
 follow-up procedures, 38
 frailty, 263–265
 for FTDs, 57–58
 guidelines for, 38–39
 for illegal drug use, 27
 individual care plans in, 37–38
 through laboratory tests, 36–37
 legal history as factor in, 29
 in LTCs, 23–24
 psychiatric consultation initiation, 23–24
 through psychiatric rounds, efficiency of, 24
 for MDD, 123–125
 as distinct from MNCDs, 67–68
 by HCPs, 125–128
 through MDS review, 30
 of medical history, 27–29
 through examination of previous records, 30
 through mental status examination, 31–32
 through neuroimaging, 37
 through neurological examination, 31
 personal history as factor in, 25–29
 of current medications, 27
- for medical history, 27–29
 for past psychiatric history, 27
 for present illness, 25–26
 through physical examination, 31
 of psychosocial needs, 21–22
 improvement of resident experiences through, 20–23
 for psychotic disorders, 173–174
 with RAIs, 30
 scales. *See also* cognitive assessment scales
 behavioral, 35–36
 for functional assessment, 35
 for pain assessment, 36
 for psychological symptoms, 35–36
 standardized, 32, 33–34
 screening questions, 20
 through screening tests, 37
 of SIBs, 26
 for sleep disturbance, 26–27
 social history as factor in, 29
 spiritual history as factor in, 29
 for SPMI, 37
 of strengths and skills, 30, 31
 of suicidality, 26
 for tobacco use, 27
 of violence, 26, 198
 for violence and aggressive behaviors, 198
- assisted living facilities, LTC in, 1
 attention training, 66, 380
 autonomy, for LTC residents, 283–284
 beneficence and, 285
 through DMC, 283–284
 during end-of-life care, 288–289
 nonmaleficence and, 285
 restriction of, cultural traditions in, 289–290
- Barthel Index, 35
 Basting, Anne, 382
 bathing strategies, with MNCD patients, 395–397
 Beers criteria, 330–333
 BEHAVE-AD. *See* Behavioral Symptoms in Alzheimer Disease
 behavioral, neurocognitive, and psychological symptoms (BNPS), 19–20, 26–27. *See also* assessment processes
 etiology of, 20
 excess disability, 20
 individual care plans for, 37–38
 medical history and, 27–29
 pharmacological principles for, 341
 protections from, 22
 behavioral assessment scales, 35–36
 Behavioral Symptoms in Alzheimer Disease (BEHAVE-AD), 36

Index

- behavioral variant FTD (bvFTD), 56
 cognitive dysfunction with, 56–59
 symptoms of, 56–59
- beneficence, 285
- benevolent deception, 374
- benzodiazepines
 for anxiety disorders, 213
 alternatives to, 347
 with MNCDs, 216
 for bipolar disorder, 155
 in DLB treatment, 55
 for end-of-life delirium, 118
 as high-risk medication, 347
 for panic disorder, 214
 in PDD treatment, 55
 for schizophrenia, 180
 for SUD, 244, 246–247
- bereavement-related MDD, 143–144
- best interest standards, 284
- BIMS. *See* Brief Interview for Mental Status
- biopsychosocial-environmental needs, 398–399
- biopsychosocial-spiritual distress (BPSD), 50, 70–78
 aging and, 95
 assessment processes for, 85–86
 biological factors for, 71–72
 case studies for, 86
 cognitive decline with, 78
 defined, 70
 environmental factors for, 72
 evidence-based approaches to, 73–75
 mild, 70–71
 moderate to severe, 70–71
 pain with, 77–78
 common causes of, 78
 prevalence of, 73–75
 psychoactive medications for, 72
 psychosocial factors for, 72–76
 agitation and aggressive behaviors, 76
 spiritual factors for, 76–77
 symptoms of, 71
 treatment for
 with bright light therapy, 83–85
 person-centered approaches in, 83–85
 with psychotropic medications, 86–88
 SPPEICE in, 83, 84–85
 with STAR approach, 85–86
 undercorrected health problems with, 73
 wandering and, 77
- bipolar disorder, 151–156
 age of onset for, 152
 clinical case for, 156
 comorbidity with, 152
- delirium and, 109
 MDD and, 152
 suicidality and, 155
 treatment strategies for, 152–156
 with antidepressants, 154–155
 evidence-based approaches to, 153–154
 with lithium, 155
 pharmacotherapy approaches, 154–155
 psychosocial approaches to, 155–156
- BMI. *See* Body Mass Index
- BNPS. *See* behavioral, neurocognitive, and psychological symptoms
- Body Mass Index (BMI), 249–250
 obesity and, 267
- Boustani, Malaz, 335–338
- BPSD. *See* biopsychosocial-spiritual distress
- brain and memory wellness plans, 65, 66, 379
 attention training in, 380
 brain-healthy nutrition, 381
 executive function improvement in, 380
 resources for, 380
- brain-healthy nutritional care, 271–272
- brexpiprazole
 for PDP, 196
 for treatment-resistant MDD, 139
- Brief Interview for Mental Status (BIMS), 34–35
- brief psychotic disorder, 189
- bright light therapy, 83–85, 376–377
- buprenorphine, 140, 355
- bupirone, 216
- bvFTDs. *See* behavioral variant FTD
- cachexia, 266–267
- CADASIL. *See* cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy
- CAM. *See* Confusion Assessment Method
- cannabis use disorder, 244–245
- caregivers. *See also* family caregivers
 assessments of, 30
 environments for, 21–22
 professional, 392
 spouses as, for MNCD patients, 96
- cariprazine
 for bipolar disorder, 155
 for PDP, 196
- CBD. *See* corticobasal degeneration
- CBT. *See* cognitive behavioral therapy
- CCRCs. *See* continuing care retirement communities
- central obesity, 267
- cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy (CADASIL), 70
- chaplain services, 373
- cholinesterase inhibitors (ChEIs), 80–82
 adverse effects of, 80–82
 for FTD, 83
 memantine and, 81
 for MNCD with psychotic symptoms, 191
- chronic anxiety disorder, 109
- chronic psychotic disorder, 109
- chronic subdural hematoma (CSDH), 62
 alcohol abuse and, 62
- chronic traumatic encephalopathy (CTE), 61
- citalopram, 86–87
- CJD. *See* Creutzfeldt-Jakob disease
- clinical cases, for psychiatric disorders
 for ADEs, 349
 agoraphobia, 214–215
 apathy syndrome, 150–151
 for bipolar disorder, 156
 delirium, 109–111, 116–118
 DLB, 54–55
 FTDs, 59–60
 for GAD, 211–213
- MDD
 MNCD with, 145–147
 after stroke, 147–148
- MNCDs, 94–95
 MDD with, 145–147
 with psychotic symptoms, 193–194
- obesity, 269
- panic disorder, 214–215
- PDD, 54–55
- personality disorders, 240
 for PIP, 341–348
 PTSD, 220–221
 secondary mania, 157
 spiritual care in, 311–312
- SPPEICE and, 369
- clonazepam, 86–87
- clozapine, 86–87
 for PDP, 196
- CMAI. *See* Cohen-Mansfield Agitation Inventory
- cognitive assessment scales, 32–35
 BIMS, 34–35
 CAM, 35, 67
 COWAT, 35
 MMSE, 32–34
 MOCA, 34–35
 SLUMS, 34–36

- cognitive behavioral therapy (CBT)
 for MDD, 132
 for SSRDs, 242
- cognitive deficit
 with MNCs, 80–97
 with schizophrenia, 179–180
- cognitive disorder. *See also* major neurocognitive disorders
 assessment tools for, 123–125, 173–174
- cognitive rehabilitation (CR), 378–379
- cognitive training strategies, 66
- Cohen-Mansfield Agitation Inventory (CMAI), 36
- computerized tomography (CT), 37
- concurrent proxy, 96
- confidentiality of personal information, 284–285
- Confusion Assessment Method (CAM), 35
 in delirium diagnosis, 67, 105–107
- constipation management, 352–353
- continuing care retirement communities (CCRCs), 12
- continuous quality improvement (CQI), 410–411
- Controlled Oral Word Association Test (COWAT), 35
- Cornell Scale for Depression in Dementia (CSDD), 35–36, 37
 for MDD, 123
- corticobasal degeneration (CBD), 56
- counseling, MNC patients and
 for family caregivers of, 97
 for sexuality and sexual expression of, 93–94
- COWAT. *See* Controlled Oral Word Association Test
- CQI. *See* continuous quality improvement
- CR. *See* cognitive rehabilitation
- creative engagement, in wellness care plans, 377
- Creutzfeldt-Jakob disease (CJD), 62–63
- CSDD. *See* Cornell Scale for Depression in Dementia
- CSDH. *See* chronic subdural hematoma
- CT. *See* computerized tomography
- CTE. *See* chronic traumatic encephalopathy
- culture
 autonomy for LTC residents and, 289–290
 end-of-life care influenced by, 313
 cyproheptadine, 260
- dance and movement therapy, 379
- DASH. *See* Dietary Approaches to Stop Hypertension
- DBS. *See* deep brain stimulation
- death rattle, 320
- decision-making capacity (DMC)
 advance care planning and, 313
 with MNCs, 95–96
 cognitive abilities and, 95
 concurrent proxy in, 96
 key principles in, 95–96
 through psychosocial-spiritual wellness care plans, 394–395
- resident abuse and, 283
- deep brain stimulation (DBS), 141
- deep transcranial magnetic stimulation, 140
- dehydration, 261–262
 diagnosis and assessment of, 261
 treatment strategies for, 261–262
- delirium
 acute psychiatric illness and, 109
 AD and, 115
 anxiety symptoms and, 218
 assessment and management of, 104–111, 112
 for family caregivers during, 114
 standardized tools for, 106–107
 work-up in, 105–111
- bipolar disorder and, 109
- chronic anxiety disorder and, exacerbation of, 109
- chronic psychotic disorder and, acute exacerbation of, 109
- clinical cases, 109–111, 116–118
- clinical presentation of, 102
- complications with, 111
- diagnosis of, 102, 105–111
 with CAM, 67, 105–107
 differential, 108–111
 misdiagnoses of, 102
 screening tools in, 105–108
- end-of-life, 118, 320
 benzodiazepines for, 118
- end-of-life care with, 301
- etiological factors for, 103–104
 psychoactive medications, 104
 reversible causes in, 104
- family caregivers and, 114
- in LTC populations
 prevention strategies against, 116
 risk factors for, 103, 104
- manic episodes and, 109
- MDD misdiagnosed as, 102, 108–109
- misdiagnoses of, 102
- MNCs and, 109
 accelerated cognitive decline with, 115
 as cause of, 115
 distinctions between, 67
 misdiagnosed as, 102, 108–109
 onset of symptoms
- acute, 102
 subacute, 102
- palliative care for, 118
- persistent, 115
- prevalence of, 102
- prevention strategies, 115–118
 Internet resources for, 117
 in LTC populations, 116
- recovery period, 114–115
- outcomes after, 115
- risk factors for, 103–104
 in LTC populations, 103, 104
 UTIs, 112
- schizophrenia as distinct from, 172
- subsyndromal, 111
- subtypes of, 103
 agitated, 103
 mixed, 103
 with normal psychomotor activity, 103
 quiet, 103
- treatment of, 111–114
 deprescribing of medications in, 113
 management of, 112
 through multimodal psychosocial-environmental interventions, 113
 nondrug approaches in, 385
 through pharmacological interventions, 113–114
- delirium with psychotic symptoms, 196
- delusional disorder, 189
- delusions
 bizarre, 165
 defined, 165
 with MNC with psychotic symptoms, 190–191
- Dementia Care Mapping, 381, 414
- dementia with Lewy Bodies (DLB), 51–55
 AD differentiated from, 52–53
 benzodiazepines for, 55
 biological factors for, 71
 clinical case, 54–55
 FTDs differentiated from, 52–53
 incidence rates for, 52–53
 RBD and, 53–54
 SPPEICE and, 55
 symptoms of, 53–54
 treatment of, with ChEIs, 80
 UTIs and, 55
- demoralization syndrome, 144
- deprescribing of medications. *See also* potentially inappropriate prescribing
 for delirium, 113
 rational, 333
- depression. *See* major depressive disorder; vascular depression

Index

- dermatologic conditions, 357–358.
See also eczema; psoriasis
- dextromethorphan-quinidine, 86–87
Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM V), 47, 102
- Dietary Approaches to Stop Hypertension (DASH), 249
- dignity-conserving approaches, in wellness care plans, 373–374
 benevolent deception in, 374
 truth telling in, 374
- dignity-conserving care, 309
 elements of, 311
- Diogenes syndrome (DS), 276–278
- disinhibition syndromes, 156
- distributive justice, 290
- DLB. *See* dementia with Lewy Bodies
- DMC. *See* decision-making capacity
- DNH orders. *See* do not hospitalize orders
- DNI orders. *See* do not intubate orders
- DNR orders. *See* do not resuscitate orders
- do not hospitalize (DNH) orders, 89–90, 312–313
- do not intubate (DNI) orders, 89–90, 312–313
- do not resuscitate (DNR) orders, 89–90
 ethical issues and, 286
- donepezil, 81
 for AD, 80
- Down syndrome, 47
- drug–drug interactions, 349–351
- DS. *See* Diogenes syndrome
- DSM V. See Diagnostic and Statistical Manual of Mental Disorders Fifth Edition*
- duloxetine, 355–356
- dysphagia, 260
- dyspnea, 319
- dysthymic disorder. *See* persistent depressive disorder
- ECT. *See* electroconvulsive therapy
- eczema, 358
- Eden Alternative, 381–382
- Edinburgh Feeding Evaluation in Dementia Questionnaire (EdFED-Q), 270
- EDS. *See* excessive daytime sleepiness
- Ekbom syndrome. *See* restless leg syndrome
- elder abuse, 274. *See also* resident abuse
- electrical deep-brain stimulation, for MDD, 140
- electroconvulsive therapy (ECT), 130, 140
- electrolyte imbalance, 261–262
- end-of-life care, for LTC residents, 7, 294–304
 aggressive behaviors during, 319
 agitation during, 319
 anticipatory prescriptions in, 315
 antidepressant medications during, 323
 anxiety and, 321–324
 applicable measures for, 301
 cultural influences on, 313
 death rattle and, 320
 with delirium, 301
 DNH orders, 89–90, 312–313
 DNI orders, 89–90, 312–313
 DNR orders, 89–90
 ethical issues and, 286
 dyspnea and, 319
 education and preparation as part of, 325–327
 estimating life expectancy and, 313–314
 ethical issues during, 287–289
 ethnicity as factor in, 313
 family caregivers during, 324–327
 education and preparation of, 325–327
 intervention approaches to, 324
 PCT support for, 325–327
 gender as possible influence on, 313
 hospice care as, 301
 life review in, 321–322
 with MDD, 301, 321–324
 with MNCDs, 303–304
 nutritional issues during, 320–321
 outcome measures for, 302–303
 pain management in, 318–319
 PCT during, 325–327
 Positive Psychiatry during, 321
 reminiscence therapy in, 321–322
 review of appropriateness of medications, 314–315
 SPPEICE in, 310
 suicidality and, 321–324
 symptom relief in, 315–317
 terms for, 295–297
- end-of-life delirium, 118, 320
 benzodiazepines for, 118
- Enriched Opportunities Program, 382
- environmental approaches and initiatives, in wellness care plans, 375–376
 bright light therapy, 376–377
 design issues in, 375
- environmental needs, 21
- epilepsy management, 356–357
- EPS. *See* extrapyramidal symptoms
- ethical issues, in long-term care, 283–291, 407
 advance directives, 284
 ANH and, withdrawal of, 289
 autonomy and, 283–284
 beneficence and, 285
 through DMC, 283–284
 during end-of-life care, 288–289
 nonmaleficence and, 285
 restriction of, cultural traditions in, 289–290
- best interest standards, 284
- confidentiality of personal information, 284–285
- distributive justice and, 290
- DNR orders and, 286
- during end-of-life care, 287–289
 autonomy and, 288–289
- euthanasia and, 288, 307–308
 mechanisms of, 286
 with MNCDs, 286–287
 with palliative sedation, 307–308
 with physician-assisted hastening of death, 307–308
- principles for, 407
- reasonable person standard, 284
- in research, 286–287
- substituted judgment, 284
- truthfulness, 287
- in use of restraints, 290–291
- valid consent, 283–284
- ethnicity
 end-of-life care and, 313
 pharmacological treatments and, 334
- euthanasia, 288, 307–308
 family caregivers and, 308
- evidence-based approach
 for anxiety disorders, 212
 to bipolar disorder, 153–154
 to BPSD, 73–75
 to insomnia, 226–227
 to LTC, 2–4, 8–9
 in MDD treatment, 134–136
 to OCD, 222–223
 for psychotic disorders, 181–182
 with psychotropic medications, 14
 to schizoaffective disorder, 183–185
 to sleep-wake disorders, 228–230
 to SUD, 245–246
- excessive daytime sleepiness (EDS), 208, 225
- excoriation disorder, 223
- executive dysfunction
 AD and, 48
 cognitive assessment scales for, 35
- executive function improvement, 380
- extrapyramidal symptoms (EPS), 50–51

- family caregivers
 delirium and, 114
 during end-of-life care, 324–327
 education and preparation of, 325–327
 intervention approaches to, 324
 PCT support for, 325–327
 euthanasia and, 308
 for MNCD patients, 96–97
 after death of patient, 97
 education and counseling for, 97
 spouses as, 96
 physician-assisted hastening of death and, 308
 in psychosocial-spiritual wellness care plans, 388
- FDA. *See* Food and Drug Administration
- fear, anxiety and, 205
- feeding skills training program, 253–255
- Fleetwood Model, 348
- fluoxetine, 139
- folate deficiency, 262
- Food and Drug Administration (FDA), 86–88
 SIBs and, drug treatment approval for, 93
- frailty
 MDD and, 149
 nutritional care and, 263–266
 assessment of, 263–265
 causes of, 265–266
 prevention and management of, 266
 testosterone replacement therapy for, 266
- frontotemporal dementias (FTDs)
 AD differentiated from, 52–53
 assessment tools for, 57–58
 bvFTD, 56
 cognitive dysfunction with, 56–59
 symptoms of, 56–59
 clinical cases for, 59–60
 clinical groups of, 56
 DLB differentiated from, 52–53
 genetic components of, 59
 symptoms of, 56
 treatment for, ChEIs in, 83
- functional assessment scales, 35
- gabapentin, 355–356
- GAD. *See* generalized anxiety disorder
- GAI. *See* Geriatric Anxiety Inventory
- galantamine, 81
 for AD, 80
- gastroesophageal reflux disease (GERD), 29
- GDS. *See* Geriatric Depression Scale
- gender. *See also* women
 end-of-life care and, 313
 LTC populations by, 6
- generalized anxiety disorder (GAD), 207–213
 clinical case for, 211–213
- GERD. *See* gastroesophageal reflux disease
- Geriatric Anxiety Inventory (GAI), 206
- Geriatric Depression Scale (GDS), 35–36, 37
 for MDD, 123
- geriatric scalpel. *See* rational prescribing
- HAART. *See* highly active antiretroviral therapy
- HAD. *See* HIV-associated dementia
- hallucination during bereavement, 189
- hallucinations, 165
 hypnagogic, 165
 hypnopompic, 165
 with MNCD with psychotic symptoms, 190
 with PDP, 194–195
 with previous medical conditions, 196
 with secondary psychotic disorders, 189–190
- haloperidol, for delirium, 113–114
- HATCh model. *See* Holistic Approach to Transformational Change model
- HCPs. *See* health care providers
- HD. *See* Huntington disease
- health care providers (HCPs)
 MDD assessment by, 125–128
 patient sexuality and, 92
- health care team members, in MNCD treatment, 79
- highly active antiretroviral therapy (HAART), 61
- high-risk medications, 341–347. *See also* opioid medications
 anticonvulsants as, 357
 antipsychotics as, 346–347
 benzodiazepines as, 347
 opioids as, 354
- HIV-associated dementia (HAD), 61
- hoarding disorder, 221–223
- Holistic Approach to Transformational Change (HATCh) model, 409–410
- holistic suffering, 311
- homicide, 198
- hospice care, 301–303
 defined, 303
 as end-of-life care, 301
- hospitalization, psychiatric aspects of, 314
- Huntington disease (HD), 61–62
- hydrocodone, 354
- hypersomnia, 208
- hyperthyroidism, 63–64
- hypnagogic hallucinations, 165
- hypnopompic hallucinations, 165
- hypoactive delirium. *See* quiet delirium
- hypoglycemia, 217
- hypothyroidism, 63–64
- IADLs. *See* instrumental activities of daily living
- IED. *See* intermittent explosive disorder
- illegal drug use, 27
- iloperidone, 196
- individual care plans, 37–38
- Individual Pleasant Activity Schedule (IPAS), 16
- inner exploration, 373
- insomnia, 230
 evidence-based approaches to, 226–227
 in LTC populations, 6
 medications linked with, 207
 nondrug approaches in treatment of, 385–386
 persistent distressing, 225
- instrumental activities of daily living (IADLs)
 functional assessment of, 1
 LTC and, 1
- intermittent explosive disorder (IED), 247
- Internet resources, for delirium prevention, 117
- IPAS. *See* Individual Pleasant Activity Schedule
- Katz Index, 35
- ketamine, 140
- Kitwood, Tom, 414
- Korsakoff syndrome, 63–64
- lamotrigine, 155
- late-onset MDD, 130
- lesbian, gay, bisexual, transgender, and queer (LGBTQ) community
 among LTC residents, 12
 MNCDs among, 92
- levetiracetam, 357
- levodopa, 78–80
- LGBTQ community. *See* lesbian, gay, bisexual, transgender, and queer community
- lidocaine, 355–356
- life review, 321–322
- lithium, 139
 for bipolar disorder, 155

Index

- Long-Term Care Ombudsman Program, 282
- long-term care (LTC) residents. *See also* end-of-life care; ethical issues, in long-term care; palliative care; resident abuse
- AD and, 5–6
- ADLs and, 1
- admittance factors for, 8
- aging populations, 12
- anxiety disorders in, 209–210
- assessment processes in, 23–24
- psychiatric consultation initiation, 23–24
- through psychiatric rounds, efficiency of, 24
- delirium in
- prevention strategies against, 116
- risk factors for, 103, 104
- ethnicity for, 12
- evidence-based approaches to, 2–4, 8–9
- facilities for, 1
- assisted living facilities, 1
- nursing homes, 1
- future research on, 12–16
- health problems and
- common, 8
- multiple opioid medication prescriptions for, 7
- untreated and undercorrected, 6–7
- IADLs and, 1
- insomnia and, 6
- key concerns in, 2–4
- for MNCDs, 1, 11, 25, 43
- epidemiology of, 1–6
- MDD and, 5
- medical complexity of, 6–8
- mood disorders in, 120
- common causes of, 121
- medications as cause of, 122
- MS among, 62
- nursing assistants and, 11
- on-site mental health services for, 9–11
- palliative care and, 7
- PCTs for, 298–300
- population demographics and, 1
- gender in, 6
- prevalence of, 2–4
- psychosocial complexity of, 6–8
- psychosocial environmental approaches to, 13
- psychosocial well-being of, 9–11
- psychotropic medication use and, 5, 6
- PTSD and, 5–6
- resident-to-resident aggression in, 6
- sex and sexuality among, 90–95
- sexual orientation for, 12
- spectrum of, 1, 2–4
- standards of care for, 290–292
- state-of-the-science care for, 290–292
- trends in characteristics of, 11–12
- for couples, 11
- demographic changes, 12
- wellness strategies in, 15–16
- loss of appetite, 260–261
- low-dose steroids, 356
- LTC. *See* long-term care residents
- lurasidone
- for bipolar disorder, 155
- for PDP, 196
- magnetic resonance imaging (MRI), 37
- for AD, 47
- MAI. *See* Medication Appropriateness Index
- major depressive disorder (MDD)
- AD as distinct from, 68
- adjustment disorder with, 142–143
- affective psychosis with, 175–177
- aging and, 95
- anxiety with, 129, 205–206
- assessment tools for, 123–125
- by HCPs, 125–128
- MNCDs as distinct from, 67–68, 127
- with atypical features, 129
- bereavement-related, 143–144
- bipolar disorder and, 152
- cachexia as distinct from, 266–267
- CBT for, 132
- CSDD for, 123
- DBS for, 141
- delirium misdiagnosed as, 102, 108–109
- demoralization syndrome and, 144
- diagnosis of, 125–128
- symptoms in, 125
- workup and, 130–132
- ECT for, 130, 140
- eczema and, 358
- end-of-life care with, 301, 321–324
- frailty and, 149
- GDS for, 123
- late-onset, 130
- among LTC populations, 5
- main features of, 128
- major types of, 129
- malnutrition and, 270–271
- antidepressants for, 271
- MCI and, 130
- medical conditions as cause of, 148–149
- with melancholic features, 129
- mild, 129
- with mixed features, 129
- MNCD with, 145–147
- clinical cases for, 145–147
- MNCDs as distinct from, 67
- assessment tools for, 67–68, 127
- neuropsychological testing for, 69
- symptoms of, 67
- moderate, 129
- moderate AD and, 50
- neurological conditions as cause of, 148–149
- neuromodulation therapies for, 140
- with PD, 148
- persistent depressive disorder, 144
- personality disorders and, 240
- PHQ for, 123
- prevalence rates for, 122
- prevention strategies, 132–142
- types of, 133–134
- psoriasis and, 358
- psychosocial approaches to, 141–142
- psychotherapy approaches to, 141–142
- with psychotic symptoms, 129, 130
- ECT for, 130
- recurrent, 129
- risk factors for, 122, 125, 126
- screening for, 123, 130
- severe, 129
- with significant anxiety symptoms, 129
- single episode, 129
- SSRIs for, 148
- after stroke, 147–148
- clinical case for, 147–148
- suicide and, myths about, 130
- symptoms of
- MNCDs as distinct from, 67
- as reaction to loss, 142
- TMS for, 140–141
- treatment for, 132–142
- with antidepressants, 132–136, 137–138, 139, 140
- complementary and alternative options in, 142
- evidence-based approaches to, 134–136
- with nutraceuticals, 140
- “serotonin syndrome” after, 139
- treatment-refractory, 139–140
- treatment-resistant, 139–140
- undernutrition and, 130–132
- vascular depression and, 147–148
- VNS for, 140, 141
- major neurocognitive disorders (MNCDs). *See also* MNCD with psychotic symptoms
- AAMI as distinct from, 64–65
- brain and memory wellness plans, 65, 66, 379

- cognitive training strategies for, 66
 SCI and, 65
 alcohol-induced, 60
 anoxic brain injury and, 63
 anxiety and, 205
 anxiety disorders and, 215–217
 clinical case for, 216–217
 treatment for, 216
 bathing strategies with, 395–397
 biopsychosocial-environmental needs with, 398–399
 CJD, 62–63
 common causes of, 44–46
 counseling for
 for family caregivers, 97
 for sexuality and sexual expression of, 93–94
 CSDH, 62
 delirium and, 109
 accelerated cognitive decline with, 115
 as cause of, 115
 distinctions between, 67
 misdiagnosed as, 102, 108–109
 diagnosis of, 43
 clarification tests in, 69–70
 differential, 64–70
 tools for, 69–70
 distress caused by, models to facilitate, 397–398
 DMC with, 95–96
 cognitive abilities and, 95
 concurrent proxy in, 96
 key principles in, 95–96
 end-of-life care with, 303–304
 ethical issues with, 286–287
 family caregivers and, caring for, 96–97
 after death of patient, 97
 education and counseling for, 97
 spouses as, 96
 HAD, 61
 HD, 61–62
 hospitalization for psychiatric emergency for, 90
 incidence rates for, 43
 LTC for, 1, 11, 25, 43
 epidemiology of, 1–6
 MCI as distinct from, 65–67
 MDD as distinct from, 67
 assessment tools for, 67–68
 neuropsychological testing for, 69
 symptoms of, 67
 MDD with, 145–147
 clinical cases for, 145–147
 meaningful activities with, 365, 367–368
 medical comorbidity with, 88–89
 medication-induced, 60
 mental health prevention for, 82
 mild, 365
 mixed, 60
 MS and, 62
 nutritional disorders with, 269–270
 symptoms of, 270
 treatment of, 270
 palliative care for, 89–90, 303–304
 differences in care for, 305–307
 key concerns regarding, 308
 personality disorders as result of, 237
 resident abuse with, 282
 reversible causes of, 63–64
 clinical presentation of, 64
 common, 63
 RPDs, 62–63
 schizophrenia as distinct from, 69
 sexuality and, 90–95
 approaches to, 92–93
 clinical cases, 94–95
 family education and counseling for, 93–94
 HCPs and, 92
 interventions for, 92–93
 among LGBTQ patients, 92
 SIBs with, 91
 sleep disorders with, 232
 “Sundowner syndrome”, 232
 SPPEICE and, 367–368
 in clinical cases, 369
 cultural expression promoted through, 369–370
 hearing and listening to resident, 367
 meaningful activities promotion through, 365, 367–368
 sexual expression promoted through, 368–369
 substance abuse-induced, 60
 from methamphetamines, 60
 from TBI, 60–61
 treatment of, 78–83
 for cognitive and functional deficits, 80–97
 goals of, 80
 by health care team members, 79
 with psychotropic medications, 86–88
 in specialized care units, 78–80
 wellness strategies for, 82
 malnutrition, MDD and, 270–271
 antidepressants for, 271
 mania, 151
 with affective psychosis, 179
 affective psychosis with, 179
 mixed, 151
 primary, 151
 secondary, 151, 156–157
 clinical case of, 157
 disinhibition syndromes and, 156
 treatment of, 156–157
 types of, 151
 manic episodes, delirium and, 109
 MCI. *See* mild cognitive impairment
 MDD. *See* major depressive disorder
 MDS. *See* minimum data set
 Medication Appropriateness Index (MAI), 330–333
 medication burden, 351–352
 medication errors, minimization of, 341–348
 medication-induced anxiety disorder, 217
 medication-induced MNCs, 60
 medication-induced psychotic disorders, 197
 medication-induced sleep-wake disorder, 232–233
 megestrol, 260
 melancholic features, MDD with, 129
 memantine, 80, 82–83
 memory
 AAMI, 64–65
 brain and memory wellness plans, 65, 66, 379
 cognitive training strategies for, 66
 SCI and, 65
 brain and memory wellness plans, 65, 66, 379
 attention training in, 380
 brain-healthy nutrition, 381
 executive function improvement in, 380
 resources for, 380
 repetition and relaxation strategies for, 66
 mental health navigator (MHN), 24
 mental health prevention for MNCs, 82
 nutritional care and, 271
 mental health professionals (MHPs). *See also* assessment processes
 examination of previous medical records, 30
 psychosocial assessments by, 20–23
 of SIBs, 26
 of sleep disturbance, 26–27
 of suicidality, 26
 of violence, 26
 mental health services
 evidence-based psychotropic medication therapy in, 14
 funding for, 12–16
 future research priorities for, 12–16
 for LTC residents, 9–11
 prevention strategies, 15–16

Index

- mental health services (cont.)
 psychosocial environmental approaches to, 13
 reasons for seeking, 10
 team members in, 10
- mental status examinations, 31–32
- methadone, 354–355
- methamphetamines, MNCDs from, 60
- methylphenidate, 230
- MHN. *See* mental health navigator
- MHPs. *See* mental health professionals
- micronutrient deficiency, 262–263
 causes of, 262
 folate deficiency, 262
 risk factors for, 262
 testing for, 263
 treatment for, 263
- Mild AD, 50
- mild BPSD, 70–71
- mild cognitive impairment (MCI), 65–67
 MDD and, 130
- mild MDD, 129
- mild MNCDs, meaningful activities with, 365
- Mild Neurocognitive Disorder (Mild NCD), 48–50
- milnacipran, 355–356
- Mini-Mental State Examination (MMSE), 32–34, 37
- minimum data set (MDS), 30
- Mini-Nutritional Assessment (MNA), 249–250
- mixed delirium, 103
- mixed major neurocognitive disorders, 60
- mixed mania, 151
- mixed psychotic disorders, 197–198
- MMSE. *See* Mini-Mental State Examination
- MNA. *See* Mini-Nutritional Assessment
- MNCD with psychotic symptoms, 190–194
 AD and, 190
 antipsychotic medications for, 192
 clinical case for, 193–194
 delusions with, 190–191
 hallucinations with, 190
 treatment of, 191–193
- MNCDs. *See* major neurocognitive disorders
- MOCA. *See* Montreal Cognitive Assessment
- modafinil, 230
- moderate AD, 50–51
 BPSD and, 50
 EPS with, 50–51
 MDD and, 50
- moderate MDD, 129
- moderate MNCD, meaningful activities with, 365
- Montessori method, 382
- Montreal Cognitive Assessment (MOCA), 34–35
- mood disorders. *See also* major depressive disorder; suicide
 apathy syndrome, 149–151
 clinical case for, 150–151
 common causes of, 149
 symptoms of, 149–150
 treatment approaches to, 150
 complications of, 122
 consequences of, 122
 in LTC populations, 120
 common causes of, 121
 medications as cause of, 122
 mania, 151
 with affective psychosis, 179
 mixed, 151
 primary, 151
 secondary, 151, 156–157
 types of, 151
 personality disorders and, 237
 prevalence of, 120–121
 SSRDs and, 241
- morphine, 354–355
- MRI. *See* magnetic resonance imaging
- MS. *See* multiple sclerosis
- MSA. *See* multiple system atrophy
- multicomponent psychosocial environmental approach, 227
- multimodal psychosocial-environmental interventions, for delirium, 113
- multiple sclerosis (MS), 62
- multiple system atrophy (MSA), 51, 54
- naloxone, 355
- naturally occurring retirement communities (NORCs), 12
- neighborhood model, for PCLTCCs, 410
- neuroimaging
 assessment through, 37
 with CT, 37
 with MRI, 37
- neuromodulation therapies, for MDD, 140
- neuropathic pain, 355–356
- Neuropsychiatric Inventory – Nursing Home (NPI – NH) version, 36
- neuroticism, 241
- nicotine use disorder, 244
- nightmare disorder, 231
- nociceptive pain, 353
- Nolan, Mike, 382
- non-24-hour sleep-wake disorder, 230–231
- nonmaleficence, 285
- nonsteroidal anti-inflammatory drugs (NSAIDs), 353–354
- NORCs. *See* naturally occurring retirement communities
- normal psychomotor activity, delirium with, 103
- norquetiapine, 113–114
- nortriptyline, 140, 355–356
- NPI – NH version. *See* Neuropsychiatric Inventory – Nursing Home version
- NSAIDs. *See* nonsteroidal anti-inflammatory drugs
- nursing assistants, in LTC facilities, 11
- nursing homes, LTC in, 1
- nutraceuticals, in MDD treatment, 140
- nutritional care. *See also* undernutrition
 ANH, 289
 anorexia and, 260–261
 of aging, 260
 brain-healthy, 271–272
 cachexia, 266–267
 dehydration and, 261–262
 diagnosis and assessment of, 261
 treatment strategies for, 261–262
 electrolyte imbalance, 261–262
 during end-of-life care, 320–321
 frailty and, 263–266
 assessment of, 263–265
 causes of, 265–266
 prevention and management of, 266
 testosterone replacement therapy for, 266
 loss of appetite and, 260–261
 medications and, 271
 mental health and, 271
 micronutrient deficiency, 262–263
 causes of, 262
 folate deficiency, 262
 risk factors for, 262
 testing for, 263
 treatment for, 263
 sarcopenia, 266
 vitamin deficiency and, 263
- nutritional disorders. *See also* malnutrition; undernutrition
 with MNCDs, 269–270
 symptoms of, 270
 treatment of, 270
- obesity, 267–269
 BMI and, 267
 causes of, 267–268
 central, 267
 clinical cases for, 269
 defined, 267
 prevalence of, 267
 quality of life and, 268–269

- risk factors for, 268
 treatment for, 268
- obsessive-compulsive and related disorders
 common types of, 205
 complications of, 206
 consequences of, 206
 hoarding disorder, 221–223
- obsessive-compulsive disorder (OCD), 221
 evidence-based approach to, 222–223
- obstructive sleep apnea/hypopnea syndrome (OSAHS), 26–27, 29, 232
- OCD. *See* obsessive-compulsive disorder
- olanzapine, 86–87
 for bipolar disorder, 155
 for delirium, 113–114
 for PDP, 196
 for treatment-resistant MDD, 139
- opioid medications. *See also* deprescribing of medications; potentially inappropriate prescribing
 adverse effects of, 354
 as high-risk medication, 354
 in LTC populations, multiple prescriptions for, 7
 in pain management, 318–319, 354–355
 alternatives to, for chronic pain, 345–346
- opioid use disorder, 245
- opioid-phobia, 353
- oral nutritional supplements, 256–260
- OSAHS. *See* obstructive sleep apnea/hypopnea syndrome
- OTC medications. *See* over-the-counter medications
- otic disorders, violence and aggressive behavior and, prevention strategies for, 202
- over-the-counter (OTC) medications, hypersomnia and, 208
- pain assessment scales, 36
- pain management
 with BPSD, 77–78
 common causes of, 78
 in end-of-life care, 318–319
 of nociceptive pain, 353
 nondrug approaches to, 384
 with NSAIDs, 353–354
 with opioid medications, 318–319, 354–355
 alternatives to, for chronic pain, 345–346
- opioid medications for, 318–319
 alternatives to, 345–346
 with PCA pump, 355
 psychiatric aspects of, 353–356
 through scheduled dosing, 353
 with tramadol, 318–319, 354
- palliative care, 294–304. *See also* end-of-life care
 applicable measures for, 301
 assessment of need for, 297–301
 components of, 304, 308
 defined, 294
 for delirium, 118
 DNH orders, 89–90
 DNI orders, 89–90
 DNR orders, 89–90
 education and training for, 311, 327
 goal of, 294–297
 for LTC residents, 7
 for MNCDs, 89–90, 303–304
 differences in care for, 305–307
 key concerns for, 308
 outcome measures for, 302–303
 terms for, 295–297
- palliative care team (PCT), 297, 298–300
 education and training for, 311, 327
 during end-of-life care, 325–327
- palliative sedation, 307–308
- panic disorder, 214–215
 causes of, 214
 clinical case of, 214–215
 treatment of, 214
- parenteral nutrition, 260
- Parkinson disease (PD)
 anxiety and, 205
 anxiety disorder and, 217
- Parkinson disease psychosis (PDP), 194–196
 hallucinations with, 194–195
 treatment strategies for, 195–196
 pharmacologic therapies in, 195–196
- Parkinson diseases dementia (PDD), 51–55
 benzodiazepines for, 55
 biological factors for, 71
 clinical case, 54–55
 incidence rates for, 54
 MDD with, 148
 MSA as cause of, 51, 54
 SPPEICE and, 55
 treatment of
 with ChEIs, 80
 with levodopa, 78–80
 UTIs and, 55
- PAS. *See* Pittsburgh Agitation Scale
- Patient Health Questionnaire (PHQ), 35–36
 for MDD, 123
- patient-controlled analgesia (PCA)
 pump, 355
- PCLTCCs. *See* person-centered long-term care communities
- PCT. *See* palliative care team
- PD. *See* Parkinson disease
- PDD. *See* Parkinson diseases dementia
- PDP. *See* Parkinson disease psychosis
- periodic limb movement disorder (PLMD), 26–27
- persistent complex bereavement disorder, 325
- persistent delirium, 115
- persistent depressive disorder, 144
- persistent distressing insomnia, 225
- personality disorders, 235–240
 aging and, 235, 236–237
 clinical case for, 240
 MDD and, 240
 MNCDs as cause of, 237
 mood disorders and, 237
 prevalence of, 235–237
 symptoms of, 235–237, 238
 treatment strategies for, 237–240
- person-centered care. *See also* spiritual sensory environmental interventions and creative engagement
 components of, 361
 defined, 361–362
- person-centered long-term care communities (PCLTCCs), 361–362, 404
 action stage of, 407–414
 activity programming in, 407
 contemplation stage, 405
 CQI in, 410–411
 culture change in, 409–410
 HATCh model for, 409–410
 neighborhood model for, 410
 regenerative care model for, 410
- facility design for, 407
 future residents of, 415
 high-quality health care in, 411–412
 initiatives in, 412
 key characteristics of, 406–407
 leadership teams in, 406, 412–413
 maintenance stage in, 414–415
 organizational partnerships with, 407, 414
 precontemplation stage, 404–405
 preparation stage, 405
 prevention programs in, 411
 primary goals of, 405
 psychosocial spiritual care in, 406
 quality of care in, 406
 resident families in, 406
 resident leadership in, 412–413
 resources for, 408–409

Index

- PCLTCCs (cont.)
 staff in, 406–407
 leadership in, 412–413
 technology use in, 407, 413–414
 value of work in, 413
- pharmacological treatments
 basic principles of, 335
 for BNPS symptoms, 341
 for bipolar disorder, 154–155
 for delirium, 113–114
 ethnic factors for, 334
 for PDP, 195–196
 risk factors with, 334
 for sleep-wake disorders, 227–230
 for undernutrition, 260
- PHQ. *See* Patient Health Questionnaire
- physical examinations, assessment
 processes through, 31
- Physical Self-Maintenance Scale (PSMS), 35
- physician-assisted hastening of death, 307–308. *See also* euthanasia
 family caregivers and, 308
- pimavanserin, 86–87
 for PDP, 196
- PIP. *See* potentially inappropriate prescribing
- Pittsburgh Agitation Scale (PAS), 36
- PLMD. *See* periodic limb movement disorder
- polypharmacy, 314–315
 PIP and, 330–333
- Positive Psychiatry, 321
- post-traumatic stress disorder (PTSD), 218–221
 causes of, 218–219
 clinical case for, 220–221
 evidence-based approaches to, 219–220
 in LTC populations, 5–6
 risk factors for, 218–219
 syndromal, 218
 symptoms of, 218
- potentially inappropriate prescribing (PIP), 330
 ADEs from, 334
 clinical case for, 349
 prevention and treatment of, 348–349
 of anticholinergic drugs
 reduction strategies for, 334–343
 safer alternatives to, 342–343
 clinical case for, 341–348
 complications from, 334
 drug–drug interactions and, 349–351
 Fleetwood Model and, 348
 of high-risk medications, 341–347
 for antipsychotics, 346–347
 for benzodiazepines, 347
- key forms of, 331–333
 minimization strategies for, 341–348
 polypharmacy and, 330–333
 prescribing cascade and, 350
 psychiatric aspects of, 352–358
 for constipation management, 352–353
 for dermatologic conditions, 357–358
 for pain management, 353–356
 for seizure disorder/epilepsy management, 356–357
 reduction strategies for, 336–338, 348, 351–352
- pramipexole, 140
- pregabalin, 355–356
- premorbid anxiety disorders, 216
 GAD, 207–213
 clinical case for, 211–213
- prescribing cascade, 350
- pressure ulcers, nondrug approaches to, 384
- prevention strategies, for psychiatric disorders
 ADEs and, 348–349
 for delirium, 115–118
 Internet resources for, 117
 in LTC populations, 116
 for MDD, 132–142
 types of, 133–134
 mental health services in, 15–16
 nutritional care, 266
 resident abuse, 276, 278–282
 with MNCDs, 282
 for suicide, 161
 for undernutrition, 254–255
 for violence and aggressive behavior and, 198–202
- primary mania, 151
- primary psychotic disorders. *See also* schizophrenia
 affective psychosis, 175–179
 clinical case for, 177–178
 mania with, 179
 MDD with, 175–177
 delusional disorder, 189
 schizoaffective disorder, 180–189
 clinical case for, 188–189
 treatment strategies for, evidence-based approaches in, 183–185
- primary RLS, 231
- probable AD, 47
- professional caregivers, 392
- progressive supranuclear palsy (PSP), 56
- Progressively Lowered Stress Threshold Model, 397–398
- PSMS. *See* Physical Self-Maintenance Scale
- psoriasis, 358
- PSP. *See* progressive supranuclear palsy
- psychiatric disorders. *See* major neurocognitive disorders; mood disorders; psychotic disorders
- psychiatric illness, acute, 109
- psychoactive medications. *See also* deprescribing of medications; potentially inappropriate prescribing
 delirium as result of, 104
- psychological symptoms, assessment of, 35–36
- psychosocial approaches and initiatives, in SPPEICE, 365–371
 through companionship, 370
 through friendships, 370
 through intergenerational connections, 370
 promotion of sense of purpose, 368
 through sexual expression, 368–369
 staff-initiated positive relationships, 365–367
- psychosocial needs, 21–22
- psychosocial-spiritual wellness care plans. *See also* spiritual sensory environmental interventions and creative engagement
 for adjustments to new home, 392–394
 animal-assisted approaches, 377
 biopsychosocial-environmental needs under, 398–399
 brain and memory wellness plans, 65, 66, 379
 attention training in, 380
 brain-healthy nutrition, 381
 executive function improvement in, 380
 resources for, 380
 components of, 362–363
 CR approach, 378–379
 through creative engagement, 377
 dance and movement therapy, 379
 decision-making through, 394–395
 dignity-conserving approaches in, 373–374
 benevolent deception in, 374
 truth telling in, 374
 environmental approaches and initiatives in, 375–376
 bright light therapy, 376–377
 design issues in, 375
 family caregivers as part of, 388
 family education as part of, 387
 family visits as part of, 386–387
 high-tech approaches, 378
 inner exploration as part of, 373
 innovative approaches to, 381–382

- sensory approaches to, 371–372
 through aromas, 372
 through music, 371
 through physical activity and exercise, 371
 through touch, 372
 simulated presence, 377
 for special populations, activities for, 379–381
 specialists in, 383–386
 spiritual approaches to, 372–373
 chaplain services, 373
 through nonreligious activities, 373
 through organized religious activities, 372–373
 through spontaneous religious experiences, 373
 strengths-based approach, 364
 for AD, 366
 for retained skills, 364
 psychotic disorders. *See also* primary psychotic disorders;
 schizophrenia; secondary psychotic disorders
 AD and, 172
 with alcohol use disorder, 197
 assessment tools for, 173–174
 brief, 189
 complications of, 171
 consequences of, 171
 delusions
 bizarre, 165
 defined, 165
 diagnosis of, 167–169
 test workup in, 176–177
 hallucinations, 165
 during bereavement, 189
 hypnagogic, 165
 hypnopompic, 165
 with previous medical conditions, 196
 medication-induced, 197
 medications as causes of, 168–169
 mixed, 197–198
 prevalence of, 165
 previous medical conditions as cause of, 196–197
 hallucinations with, 196
 treatment strategies for, 197
 risk factors for, 170
 substance-induced, 197
 treatment strategies for
 with antipsychotic medications, 185–187
 evidence-based approaches in, 181–182
 with previous medical conditions, 197
 types of, 166–167, 168
 violence and aggressive behavior
 and, 165, 198–202
 assessment of, 198
 homicide and, 198
 prevention strategies for, 198–202
 protective factors for, 201
 risk factors for, 199–200
 psychotropic medications. *See also*
 deprescribing of medications;
 potentially inappropriate prescribing
 appropriate indications for prescriptions, 339–340
 for BPSD, 86–88
 evidence-based approaches to, 14
 FDA approval of, 86–88
 in LTC populations, 5, 6
 for MNCDS, 86–88
 with renal impairment, 338–344
 PTSD. *See* post-traumatic stress disorder
 quality of life, obesity and, 268–269
 quetiapine, 86–87
 for bipolar disorder, 155
 for delirium, 113–114
 for MNCDS with psychotic symptoms, 191
 for PDP, 196
 for treatment-resistant MDD, 139
 quiet delirium, 103
 RAIs. *See* resident assessment instrument
 ramelteon, 86–87
 rapidly progressive dementias (RPDs), 62–63
 rational deprescribing, 333
 RBD. *See* REM sleep behavior disorder
 reasonable person standard, 284
 recovery period, after delirium, 114–115
 outcomes during, 115
 recurrent MDD, 129
 regenerative care model, for PCLTCCs, 410
 REM sleep behavior disorder (RBD), 26–27, 231
 DLB and, 53–54
 reminiscence therapy, 321–322
 renal impairment, psychotropic medications with, 338–344
 repetition and relaxation strategies, for memory, 66
 resident abuse, 274–283
 defined, 274
 differential diagnosis of, 276–278
 DMC and, 283
 DS and, 276–278
 interpersonal violence in, 274
 Long-Term Care Ombudsman Program for, 282
 management of, 280–281
 neglect as, 274
 prevalence of, 276
 prevention strategies for, 276, 278–282
 with MNCDS, 282
 risk factors for, 277–278
 screening questions for, 279
 SIBs and, 274
 treatment for, 282–283
 types of, 275–276
 verbal abuse, 274
 resident assessment instrument (RAI), 30
 restless leg syndrome (RLS), 26–27, 231–232
 primary, 231
 secondary, 231
 treatment for, 231–232
 restraints, use of, 290–291
 reversible causes of MNCDS, 63–64
 clinical presentation of, 64
 common, 63
 risperidone, 61, 86–87
 for delirium, 113–114
 rivastigmine, 81
 for AD, 80
 RLS. *See* restless leg syndrome
 RPDs. *See* rapidly progressive dementias
 Saint Louis University Mental State Exam (SLUMS), 34–36
 sarcopenia, 266
 schizoaffective disorder, 180–189
 clinical case for, 188–189
 treatment strategies for, evidence-based approaches in, 183–185
 schizophrenia, 69, 179–187
 age of onset for, 179
 cognitive deficit with, 179–180
 delirium as distinct from, 172
 prevalence of, 179
 suicide risks and, 180
 symptoms of, 170, 171, 179
 treatment strategies for, 180–187
 with antipsychotic medications, 180
 with benzodiazepines, 180
 evidence-based approaches in, 183–185
 undernutrition and, 175
 SCI. *See* subjective cognitive impairment
 screening tests, 37
 CSDD, 37

Index

- screening tests (cont.)
 GDS, 37
 MMSE, 37
 SLUMS, 37
- Screening Tool of Older Person's Potentially Inappropriate Prescription (STOPP), 330–333
- Screening Tool to Alert doctors for the Right Treatment (START), 330–333
- SD. *See* semantic dementia
- secondary mania, 151, 156–157
 clinical case of, 157
 disinhibition syndromes and, 156
 treatment of, 156–157
- secondary psychotic disorders, 189–196. *See also* MNCD with psychotic symptoms
- delirium with psychotic symptoms, 196
- hallucinations with, 189–190
- PDP, 194–196
 pharmacologic therapies in, 195–196
 treatment strategies for, 195–196
 symptoms of, 189–190
 treatment of, 190
- secondary RLS, 231
- sedation. *See* palliative sedation
- seizure disorder management, 356–357
- selective serotonin reuptake inhibitors (SSRIs), 88
 for MDDs, 148
 for SIBs, 93
- selegiline, 140
- semantic dementia (SD), 56
- sensory approaches, in wellness care plans, 371–372
 through aromas, 372
 through music, 371
 through physical activity and exercise, 371
 through touch, 372
- “serotonin syndrome,” 139
- severe AD, 51
- severe and persistent mental illness (SPMI), 37
- severe MDD, 129
- severe MNCD, meaningful activities with, 365
- sexuality
 in LTCs, 90–95
 MNCDs and, 90–95
 approaches to, 92–93
 clinical cases, 94–95
 family education and counseling for, 93–94
 HCPs and, 92
 interventions for, 92–93
 among LGBTQ patients, 92
- sexually inappropriate behaviors (SIBs)
 assessment of, 26
 with MNCDs, 91
 resident abuse and, 274
 SSRIs for, 93
- simulated presence, 377
- single episode MDD, 129
- Six Senses Program, 382
- sleep disorders, 26–27. *See also* sleep-wake disorders
 with MNCDs, 232
 “Sundowner syndrome,” 232
- sleep disturbances, assessment of, 26–27
- sleep-wake disorders, 206, 223–231
 aging and, 225
 complications of, 206
 consequences of, 206
 diagnosis of, 224
 EDS, 208, 225
 environmental factors for, 225
 etiology of, 223, 225
 hypersomnia, OTC medications linked with, 208
- insomnia, 230
 evidence-based approaches to, 226–227
 in LTC populations, 6
 medications linked with, 207
 persistent distressing, 225
 medication-induced, 232–233
 nightmare disorder, 231
 non-24-hour, 230–231
 OSAHS, 26–27, 29, 232
 prevalence of, 223
 prior medical conditions as cause of, 233
 psychosocial factors for, 225
- RBD, 26–27, 231
 DLB and, 53–54
- RLS, 26–27, 231–232
 primary, 231
 secondary, 231
 treatment for, 231–232
- treatment for, 225–230
 evidence-based approach in, 228–230
 multicomponent psychosocial environmental approach in, 227
 pharmacological approach in, 227–230
- SLUMS. *See* Saint Louis University Mental State Exam
- Snoezelen program, 382
- social anxiety disorders, 215
- somatic symptom and related disorders (SSRDs), 240–242
 mood disorders as distinct from, 241
 neuroticism and, 241
- risk factors for, 241
 treatment strategies for, 242
 with CBT, 242
- Spark of Life Approach program, 382
- specific phobias, 215
- spiritual approaches, in wellness care plans, 372–373
 chaplain services, 373
 through nonreligious activities, 373
 through organized religious activities, 372–373
 through spontaneous religious experiences, 373
- spiritual care, 309–312
 clinical case for, 311–312
- spiritual sensory environmental interventions and creative engagement (SPPEICE), 9, 362–364. *See also* psychosocial approaches and initiatives
- barriers to implementation of, 383
 key strategies to, 386
 for BPSD, 83, 84–85
 through community promotion, 370
 distress reduction through, 398–399
 de-escalation strategies for, 401
 for DLB, 55
 in end-of-life care, 310
 individualized approach to, 364–365
 for MNCD with psychotic symptoms, 191
 for PDD, 55
 professional caregivers, 392
 for residents with MNCD, 367–368
 in clinical cases, 369
 cultural expression, 369–370
 hearing and listening to resident, 367
 meaningful activities for, 365, 367–368
 sexual expression, 368–369
 specialists in, 383–386
 staff education and training for, 388–391
 for staff-family relationship improvement, 391
- SPMI. *See* severe and persistent mental illness
- spontaneous religious experiences, 373
- spouses, as caregivers, 96
- SPPEICE. *See* spiritual sensory environmental interventions and creative engagement
- SSRDs. *See* somatic symptom and related disorders
- SSRIs. *See* selective serotonin reuptake inhibitors
- standardized assessment scales, 32, 33–34

- standards of care, for LTC residents, 290–292
- STAR approach, to BPSD, 85–86
- START. *See* Screening Tool to Alert doctors for the Right Treatment
- state-of-the-science care, for LTC residents, 290–292
- STOPP. *See* Screening Tool of Older Person's Potentially inappropriate Prescription
- strengths-based approach, in wellness care plans, 364
 for AD, 366
 for retained skills, 364
- stroke, MDD after, 147–148
 clinical case for, 147–148
- subjective cognitive impairment (SCI), 65
- substance abuse
 anxiety disorders and, 218
 MNCDs from, 60
 psychotic disorders and, 197
- substance use disorders (SUD), 242–244
 treatment strategies for, 245–247
 with benzodiazepines, 244, 246–247
 evidence-based approach to, 245–246
- substance-induced psychotic disorder, 197
- substance-related and addictive disorders, 242–247. *See also* alcohol abuse; substance abuse
 alcohol use disorder, 244
 cannabis use disorder, 244–245
 nicotine use disorder, 244
 opioid use disorder, 245
 SUD, 242–244
 treatment strategies for, 244, 245–247
- substituted judgment, 284
- subsyndromal delirium, 111
- subsyndromal PTSD, 218
- SUD. *See* substance use disorders
- suicide, suicidality and, 158–161
 assessment of, 26, 161
 bipolar disorder and, 155
 during end-of-life care, 321–324
 MDD and, myths about, 130
 prevalence of, 160–161
 prevention strategies for, 161
 protective factors for, 160
 risk factors for, 158–159, 160, 161
 “Sundowner syndrome,” 232
- Taylor, Richard, 361
- TBI. *See* traumatic brain injury
- technology use, in PCLTCCs, 407, 413–414
- telehealth, 286
- terminal-stage AD, 51
- testosterone replacement therapy, 266
- tetrabenazine, 61
- TimeSlips, 382
- tizanidine, 356
- TMS. *See* transcranial magnetic stimulation
- tobacco use, 27
- training
 for attention, 66, 380
 cognitive training strategies, 66
 feeding skills training program, 253–255
 for palliative care staff, 311, 327
 for SPPEICE, 388–391
 for staff-family relationship improvement, 391
- tramadol, 318–319, 354
- transcranial magnetic stimulation (TMS), 140–141
- transmucosal fentanyl, 319
- trauma and stress-related disorders, 218–221. *See also* post-traumatic stress disorder
 common types of, 205
 complications of, 206
 consequences of, 206
 excoriation disorder, 223
- traumatic brain injury (TBI)
 CTE, 61
 MNCDs from, 60–61
- treatment-refractory MDD, 139–140
- treatment-resistant MDD, 139–140
- trospium, 115
- truthfulness
 in long-term care, 287
 in psychosocial-spiritual wellness care plans, 374
- undernutrition, 249–260
 assessment of
 with MNA, 249–250
 tests and measurements for, 253
- BMI and, 249–250
 common causes of, 252
 complications of, 249
 defined, 249–250
 dysphagia and, 260
 manifestations of, 250–253
 MDD and, 130–132
- prevention strategies for, 254–255
- schizophrenia and, 175
- treatment strategies for, 253, 254–255
 with feeding skills training program, 253–255
- oral nutritional supplements in, 256–260
- parenteral nutrition, 260
 with pharmacological therapies, 260
 through various diets, 256–259
- Universal Transfer Form (UTF), 30
- urinary tract infections (UTIs), 55
 delirium and, 112
- UTF. *See* Universal Transfer Form
- UTIs. *See* urinary tract infections
- VaD. *See* vascular dementia
- vagal nerve stimulation (VNS), for MDD, 140, 141
- valid consent, 283–284
- vascular dementia (VaD), 55
 biological factors for, 71
 causes of
 cerebrovascular disease, 55
 strokes, 55
 symptoms of, 55
- vascular depression, 147–148
- verbal abuse, 274
- violence
 assessment of, 26, 198
 psychotic disorders and, 165, 198–202
 assessment of, 198
 homicide and, 198
 prevention strategies for, 198–202
 protective factors for, 201
 risk factors for, 199–200
 in resident abuse, 274
- vitamin deficiency, 263
- VNS. *See* vagal nerve stimulation
- wandering, 77
- wasting disease. *See* cachexia
- wellness strategies. *See also* psychosocial-spiritual wellness care plans
 for AAMI, 65, 66, 379
 in LTC residents, 15–16
 for MNCDs, 82
- Wernicke encephalopathy, 63–64
- women, in LTC populations, 6
- ziprasidone, 196